Skip to main content
Cellular and Molecular Life Sciences: CMLS logoLink to Cellular and Molecular Life Sciences: CMLS
. 2008 Oct 14;65(23):3830–3838. doi: 10.1007/s00018-008-8442-2

A combined artificial chromosome-stem cell therapy method in a model experiment aimed at the treatment of Krabbe’s disease in the Twitcher mouse

R L Katona 1,, I Sinkó 1, G Holló 1, K Székely Szűcs 1, T Praznovszky 1, J Kereső 1, E Csonka 1, K Fodor 1, I Cserpán 1, B Szakál 1, P Blazsó 1, A Udvardy 2, G Hadlaczky 1
PMCID: PMC11131723  PMID: 18850314

Abstract.

Mammalian artificial chromosomes (MACs) are safe, stable, non-integrating genetic vectors with almost unlimited therapeutic transgene-carrying capacity. The combination of MAC and stem cell technologies offers a new strategy for stem cell-based therapy, the efficacy of which was confirmed and validated by using a mouse model of a devastating monogenic disease, galactocerebrosidase deficiency (Krabbe’s disease). Therapeutic MACs were generated by sequence-specific loading of galactocerebrosidase transgenes into a platform MAC, and stable, pluripotent mouse embryonic stem cell lines were established with these chromosomes. The transgenic stem cells were thoroughly characterized and used to produce chimeric mice on the mutant genetic background. The lifespan of these chimeras was increased twofold, verifying the feasibility of the development of MAC-stem cell systems for the delivery of therapeutic genes in stem cells to treat genetic diseases and cancers, and to produce cell types for cell replacement therapies.

Keywords. Mammalian artificial chromosome, stem cell, Krabbe’s disease, transgenic mouse, gene therapy

Footnotes

Received 29 July 2008; received after revision 22 September 2008; accepted 24 September 2008


Articles from Cellular and Molecular Life Sciences: CMLS are provided here courtesy of Springer

RESOURCES